Trial · NCT01323400
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
NCT01323400, Phase 2, Completed, Centre Leon Berard
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST). Trials, record NCT01323400. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01323400
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
- NCT number
- NCT01323400
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 81 participants, actual
- Lead sponsor
- Centre Leon Berard
- Conditions
- GIST
- Interventions
- Pazopanib, Best supportive care
- First posted
- 2011-03-25
- Last updated
- 2016-02-25
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | Within 16 months after the first inclusion, from the date of randomisation until the date of the first documented progression or death from any cause | |
| Secondary | Overall survival | Within 16 months after the first inclusion, from the date of randomisation until the date of death from any cause | |
| Secondary | Objective tumour response rate (RECIST v.1.1) at 4 months | 4 months after randomisation | |
| Secondary | Best response (RECIST v.1.1) obtained during the study | Within 16 months after the first inclusion | |
| Secondary | Tolerance profile (NCI-CTCAE v.4.0) | Within 16 months after the first inclusion | |
| Secondary | Pattern of progression-free survival in the different molecular subtypes | Within 16 months after the first inclusion, from the date of randomisation until the date of the first documented progression or death from any cause | |
| Secondary | Intra and inter-patient variability of the Cmin of pazopanib | After 4 weeks, 10 weeks, 16 weeks of pazopanib treatment and at time of progression | |
| Secondary | Progression-free survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression | Within 16 months after the first inclusion, from the date of the first pazopanib administration until the date of the first documented progression or death from any cause | |
| Secondary | Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression | Within 16 months after the first inclusion, from the date of the first pazopanib administration until the date of death from any cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers26
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01323400
GET https://conductscience.org/api/trials/v1/NCT01323400/papers?page=2